A record subscription rate was witnessed on the last day of bidding for Rubicon Research IPO that ended on October 13.
With an issue size of Rs 1,377 crore, Rubicon Research IPO was subscribed 103 times by interested investors throughout the three days of public bidding.
Review of Rubicon Research Ltd IPO
— Paryan Sharma (@Paryan_Sharma) October 12, 2025
I am Applying for Small-Reasonable Listing Gains and Long Term ✅
Pointers:
▫️Rubicon is the Fastest Growing Indian pharmaceuticals formulations company, almost 7x higher than the average of peers
- Company is ranked among top 12 Indian… pic.twitter.com/yWpoJeikl7
As per the information available on the official website of the National Stock Exchange (NSE), Qualified Institutional Buyers subscribed 130 times their share. Meanwhile, Non-Institutional Investors and Retail Individual Investors bid 97 times and 35 times their allotted shares, respectively.
IPO details:
For a minimum investment of Rs 13,830, investors could place their bids for 30 shares. The price range is set at Rs 461-485.
Rubicon IPO bidding started on October 9 and ended on October 13. The shares are expected to be allotted on October 14 and the listing will take place on October 16, as per the information available on the official website of NSE.
Multiple media reports stated the grey market premium (GMP) of Rubicon Research IPO to be between Rs 95-110. With an upper band price set at Rs 485, market analysts expect a 22 per cent gain after listing for the investors.
About Rubicon
The company, established in 1999, evolved from a contract development services provider to a focused pharmaceutical company developing, manufacturing, and marketing specialty and generic prescription products primarily for the US market.
Rubicon operates through two key US subsidiaries, AdvaGen Pharma for generic products and Validus for branded speciality pharmaceuticals. The company's manufacturing capabilities span three US FDA-inspected facilities in India, capable of producing oral solids, liquids, and nasal sprays. It also ranks 9th globally among companies securing speciality pharma approvals between 2019 and 2024, having received seven approvals during this period.
